MA51337A - Inhibiteurs spiro exo-aza de l'interaction ménine-mll - Google Patents
Inhibiteurs spiro exo-aza de l'interaction ménine-mllInfo
- Publication number
- MA51337A MA51337A MA051337A MA51337A MA51337A MA 51337 A MA51337 A MA 51337A MA 051337 A MA051337 A MA 051337A MA 51337 A MA51337 A MA 51337A MA 51337 A MA51337 A MA 51337A
- Authority
- MA
- Morocco
- Prior art keywords
- menin
- exo
- spiro
- mll interaction
- aza
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 230000003993 interaction Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017117536 | 2017-12-20 | ||
| CN2018091521 | 2018-06-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51337A true MA51337A (fr) | 2020-10-28 |
Family
ID=66993097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051337A MA51337A (fr) | 2017-12-20 | 2018-12-19 | Inhibiteurs spiro exo-aza de l'interaction ménine-mll |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230039917A1 (fr) |
| EP (1) | EP3728260A4 (fr) |
| JP (1) | JP7307729B2 (fr) |
| KR (1) | KR20200101389A (fr) |
| CN (1) | CN111601807B (fr) |
| AU (1) | AU2018389145B2 (fr) |
| BR (1) | BR112020012461A2 (fr) |
| CA (1) | CA3083624A1 (fr) |
| IL (1) | IL275457A (fr) |
| MA (1) | MA51337A (fr) |
| MX (1) | MX2020006594A (fr) |
| WO (1) | WO2019120209A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3468966T (pt) | 2016-06-10 | 2020-11-10 | Vitae Pharmaceuticals Llc | Inibidores da interação menina-mll |
| CN110950818B (zh) * | 2019-12-18 | 2021-12-28 | 浙江海翔药业股份有限公司 | 顺式-2,6-二甲基吗啉的纯化方法 |
| UA129208C2 (uk) | 2019-12-19 | 2025-02-05 | Янссен Фармацевтика Нв | Заміщені спіропохідні з прямим ланцюгом |
| CN114478568A (zh) * | 2020-10-27 | 2022-05-13 | 苏州优理生物医药科技有限公司 | 一种噻吩并嘧啶类化合物、包含其药物组合物及其应用 |
| AU2022222458A1 (en) * | 2021-02-19 | 2023-08-24 | Kalvista Pharmaceuticals Limited | Factor xiia inhibitors |
| CN117730081A (zh) | 2021-05-08 | 2024-03-19 | 詹森药业有限公司 | 取代的螺环衍生物 |
| BR112023023154A2 (pt) | 2021-05-08 | 2024-01-23 | Janssen Pharmaceutica Nv | Derivados espiro substituídos |
| EP4337203A4 (fr) * | 2021-05-14 | 2025-04-09 | Syndax Pharmaceuticals, Inc. | Inhibiteurs de l'interaction ménine-mll |
| WO2024110649A1 (fr) | 2022-11-24 | 2024-05-30 | Oryzon Genomics, S.A. | Combinaisons d'inhibiteurs de lsd1 et d'inhibiteurs de ménine pour le traitement du cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015011576A (es) * | 2013-03-13 | 2016-05-16 | Univ Michigan | Composiciones que comprenden compuestos de tienopirimidina y tienopiridina y metodos para usar los mismos. |
| AR104020A1 (es) * | 2015-06-04 | 2017-06-21 | Kura Oncology Inc | Métodos y composiciones para inhibir la interacción de menina con proteínas mill |
| EP3394064A1 (fr) * | 2015-12-22 | 2018-10-31 | Vitae Pharmaceuticals, Inc. | Inhibiteurs de l'interaction ménine-mll |
| WO2017207387A1 (fr) * | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Dérivés d'azétidine spiro condensés en tant qu'inhibiteurs de l'interaction ménine-mml1 |
| PT3468966T (pt) * | 2016-06-10 | 2020-11-10 | Vitae Pharmaceuticals Llc | Inibidores da interação menina-mll |
| TWI738864B (zh) * | 2016-09-14 | 2021-09-11 | 比利時商健生藥品公司 | Ｍｅｎｉｎ-ｍｌｌ相互作用之螺二環抑制劑 |
| US11396517B1 (en) * | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
-
2018
- 2018-12-19 CA CA3083624A patent/CA3083624A1/fr active Pending
- 2018-12-19 JP JP2020534167A patent/JP7307729B2/ja active Active
- 2018-12-19 MA MA051337A patent/MA51337A/fr unknown
- 2018-12-19 MX MX2020006594A patent/MX2020006594A/es unknown
- 2018-12-19 EP EP18892193.6A patent/EP3728260A4/fr active Pending
- 2018-12-19 AU AU2018389145A patent/AU2018389145B2/en active Active
- 2018-12-19 CN CN201880082454.4A patent/CN111601807B/zh active Active
- 2018-12-19 KR KR1020207020200A patent/KR20200101389A/ko active Pending
- 2018-12-19 BR BR112020012461-3A patent/BR112020012461A2/pt unknown
- 2018-12-19 WO PCT/CN2018/121960 patent/WO2019120209A1/fr not_active Ceased
-
2020
- 2020-06-17 IL IL275457A patent/IL275457A/en unknown
-
2022
- 2022-05-02 US US17/734,413 patent/US20230039917A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020123548A (ru) | 2022-01-20 |
| RU2020123548A3 (fr) | 2022-02-17 |
| EP3728260A4 (fr) | 2021-08-11 |
| CN111601807A (zh) | 2020-08-28 |
| US20230039917A1 (en) | 2023-02-09 |
| BR112020012461A2 (pt) | 2020-11-24 |
| EP3728260A1 (fr) | 2020-10-28 |
| MX2020006594A (es) | 2020-09-09 |
| CA3083624A1 (fr) | 2019-06-27 |
| IL275457A (en) | 2020-08-31 |
| CN111601807B (zh) | 2023-03-31 |
| AU2018389145A1 (en) | 2020-05-21 |
| AU2018389145B2 (en) | 2023-02-02 |
| JP7307729B2 (ja) | 2023-07-12 |
| WO2019120209A1 (fr) | 2019-06-27 |
| KR20200101389A (ko) | 2020-08-27 |
| JP2021506882A (ja) | 2021-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3353328A4 (fr) | Modulateurs de l'expression de kras | |
| IL263586B (en) | Inhibitors of the menin-mll interaction | |
| HUE060078T2 (hu) | CDK7 gátlására alkalmas vegyületek | |
| MA51337A (fr) | Inhibiteurs spiro exo-aza de l'interaction ménine-mll | |
| MA46228A (fr) | Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll | |
| DK3512850T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| MA46180A (fr) | Analogues de l'amyline | |
| EP3526328A4 (fr) | Polythérapie pour l'inhibition de c3 | |
| EP3353156A4 (fr) | Inhibiteurs de l'autopalmitoylation du facteur de transcription tead | |
| EP3732239A4 (fr) | Composition de polyéthylène | |
| PT3368534T (pt) | Ditosilato de valbenazina e polimorfos do mesmo | |
| EP3509581A4 (fr) | Formulations de (r | |
| PT3548033T (pt) | Compostos e respectivos métodos de utilização | |
| MA52814A (fr) | Inhibiteurs de bromodomaine | |
| EP3443094A4 (fr) | Procédés de réduction de l'expression de c9orf72 | |
| EP3415146A4 (fr) | Inhibiteur de l'activation des inflammasomes | |
| PT3457851T (pt) | Derivados de sobetiroma | |
| IL272851A (en) | Methods of using dipivefrin | |
| MA49006A (fr) | Inhibiteurs d'ip6k | |
| EP3449001A4 (fr) | Inhibition de l'arnmi mir-22 par apt-110 | |
| EP3347334A4 (fr) | Déshydrohalogénation d'hydrochlorofluorocarbones | |
| EP3415524A4 (fr) | INHIBITEUR D'EXPRESSION DE L'a-SYNUCLÉINE | |
| EP3556758A4 (fr) | Inhibiteur de cdk4/6 | |
| EP3484854A4 (fr) | Inhibiteurs de l'apoptose | |
| DK3286317T3 (da) | Dynamin 2-inhibitor til behandlingen af duchennes muskeldystrofi |